Robert W. Baird Lowers Immutep (NASDAQ:IMMP) Price Target to $6.00

Immutep (NASDAQ:IMMP - Free Report) had its target price decreased by Robert W. Baird from $7.00 to $6.00 in a research note released on Thursday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company's stock.

Separately, Capital One Financial assumed coverage on Immutep in a report on Friday, May 17th. They set an overweight rating and a $10.00 price target for the company.

Immutep Stock Performance

Shares of NASDAQ IMMP traded down $0.90 during midday trading on Thursday, hitting $1.87. 2,523,912 shares of the company's stock were exchanged, compared to its average volume of 216,896. Immutep has a 12 month low of $1.58 and a 12 month high of $3.34. The company's 50 day moving average price is $2.76 and its 200 day moving average price is $2.51.

Hedge Funds Weigh In On Immutep

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMMP. PFG Investments LLC acquired a new position in shares of Immutep during the 1st quarter worth $119,000. Oracle Investment Management Inc. raised its holdings in shares of Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock worth $1,316,000 after buying an additional 48,449 shares in the last quarter. Virtu Financial LLC raised its holdings in shares of Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after buying an additional 32,864 shares in the last quarter. Meridian Wealth Management LLC raised its holdings in shares of Immutep by 3.6% during the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company's stock worth $774,000 after buying an additional 11,250 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock worth $82,000 after buying an additional 4,700 shares in the last quarter. 2.32% of the stock is owned by institutional investors and hedge funds.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.